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A B S T R A C T
Background: Benzene is a known occupational carcinogen associated with increased risk of hematologic
cancers, but the relationships between quantity of passive benzene exposure through residential
proximity to toxic release sites, duration of exposure, lag time from exposure to cancer development, and
lymphoma risk remain unclear.
Methods: We collected release data through the Environmental Protection Agency’s Toxics Release
Inventory (TRI) from 1989 to 2003, which included location of benzene release sites, years when release
occurred, and amount of release. We also collected data on incident cases of non-Hodgkin lymphoma
(NHL) from the Georgia Comprehensive Cancer Registry (GCCR) for the years 1999–2008. We constructed
distance-decay surrogate exposure metrics and Poisson and negative binomial regression models of NHL
incidence to quantify associations between passive exposure to benzene and NHL risk and examined the
impact of amount, duration of exposure, and lag time on cancer development. Akaike’s information
criteria (AIC) were used to determine the scaling factors for benzene dispersion and exposure periods
that best predicted NHL risk.
Results: Using a range of scaling factors and exposure periods, we found that increased levels of passive
benzene exposure were associated with higher risk of NHL. The best ﬁtting model, with a scaling factor of
4 kilometers (km) and exposure period of 1989–1993, showed that higher exposure levels were
associated with increased NHL risk (Level 4 (1.1–160 kilograms (kg)) vs. Level 1: risk ratio 1.56 [1.44–1.68],
Level 5 (>160 kg) vs. Level 1: 1.60 [1.48–1.74]).
Conclusions: Higher levels of passive benzene exposure are associated with increased NHL risk across
various lag periods. Additional epidemiological studies are needed to reﬁne these models and better
quantify the expected total passive benzene exposure in areas surrounding release sites.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Benzene, toluene, ethylbenzene, and xylene (BTEX) are volatile
organic compounds (VOC) that are typically found in petroleum
products, coal tar and various chemical product formulations, and
have been associated with increased cancer risk [1]. Among these,
benzene is a VOC that has been consistently linked to hematologic
cancers such as leukemia and lymphoma through occupational* Corresponding author at: 1518 Clifton Road NE, Atlanta, GA 30322, USA.
E-mail address: jswitch@emory.edu (J.M. Switchenko).
http://dx.doi.org/10.1016/j.canep.2016.01.008
1877-7821/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article unexposure [2–6]. Benzene is a widely used chemical that ranks in the
top 20 chemicals for production volume and is used in the
production of some types of rubbers, dyes, pesticides, lubricants,
and detergents [7]. Studies have shown that subjects in
occupations exposed to low levels of airborne benzene exhibit
increased incidence of DNA methylation alterations common in
acute myelogenous leukemia and other cancer tissues [8], in
addition to lower levels of white blood cell and platelet counts [9].
The US Environmental Protection Agency (EPA) estimates that
the main routes of benzene exposure occur through the air, via
cigarette smoking and exposures from consumer products, car
emissions, trafﬁc exhaust fumes, and gas stations [10]. In addition,der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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benzene than other areas and thus contribute to the amount of
passive benzene to which individuals are exposed [7].
The relationship between passive benzene exposure and
hematologic cancers is less certain than for occupational exposure.
Among hematologic malignancies, NHL is the most common. In
2015, an estimated 71,850 people in the US will be diagnosed with
NHL, and 19,790 will die from this cancer [11]. For reasons that
remain unclear, NHL incidence rates increased over the last half of
the 20th century and only recently stabilized. Although the
descriptive epidemiology of NHL has been well characterized using
population-based cancer registry data over the last several
decades, the etiology of NHL and its speciﬁc subtypes is less well
understood [12]. To address this problem, InterLymph engaged in a
worldwide project to pool case-control studies and perform pooled
analyses to maximize the statistical power for identifying risk
factors across NHL subtypes. A recent series of publications
identiﬁed environmental, lifestyle, and clinical risk factors for
several NHL subtypes [13–16] and recent genome-wide association
studies (GWAS) identiﬁed single nucleotide variants associated
with increased risk of diffuse large B cell lymphoma [17–23], the
most common NHL subtype. Despite these recent seminal
advances, relatively little is known about the spatial epidemiology
of NHL. Although some studies support links between toxic
exposures and NHL incidence, others do not, and thus considerable
controversy remains [24–26]. The series of InterLymph studies
previously mentioned also identiﬁed etiologic commonality across
NHL subtypes and highlighted occupational history as linked to
NHL [15].
To improve our understanding of the relationship between
lymphoma risk and passive exposure through proximity to release
sites, we previously collected data from the EPA’s TRI and modeled
the number of lymphoma cases as a function of indirect exposure
to benzene using mean distance to benzene release sites in the
state of Georgia [27]. This research identiﬁed passive benzene
exposure as being associated with increased risk of NHL, but failedig. 1. Effect of scaling factor on the measure of distance decay exposure over
creasing distances. Exposure at the point source (Distance = 0 km) is assumed to
e 1000.to clarify its impact on NHL risk in terms of quantity of exposure,
lag time from exposure to cancer development, and duration of
exposure.
Our prior model simpliﬁed estimation of residential exposure
patterns by determining the average distance from all benzene
releasing sites for a given location. While this approach identiﬁed
associations between benzene exposure and increased lymphoma
risk, mean distance from release sites remains a crude measure
that does not take into account the magnitude of passive exposure.
An individual’s personal exposure to VOCs is related to indoor and
outdoor sources, including points of release such as TRI facilities
and non-point releases such as on-road, secondary, and back-
ground. Although the contribution of point sources to the outdoor
concentration of a VOC and to an individual’s total exposure may
be small, differences in VOC release amount and proximity may
result in distinct levels of risk for populations with varying degrees
of exposure. We sought to examine the collective impact on the
relationships between residential benzene exposure and NHL risk
as inﬂuenced by distance from TRI release sites, amount of benzene
released per site, and lag time from the period of release.
2. Data
We collected lymphoma incidence data from the GCCR for
patients diagnosed with NHL from 1999 to 2008, benzene release
data within Georgia from the EPA’s TRI from 1989 to 2003, and
state population characteristics from United States Census Bureau
data for the year 2000. In the 2000 US census, there were 1618
census tracts within Georgia, of which 1616 had available
population and demographic data. Data on sex, age, and race
were obtained from Summary File 1 from the Census 2000 Data for
the United States [28]. Georgia tract boundaries obtained from the
Census Bureau’s 2000 TIGER/Line ﬁles [29] were utilized for the
purposes of allocating GCCR cases to Georgia census tracts. Census
data for median year moved into residence (MYMI) were collected
in our previous study, but were not found to be associated with
NHL risk [27]. As a result, MYMI was not considered for further
modeling purposes. Additionally, we collected Summary Files 3
and 4 socioeconomic status (SES) Sample Data, speciﬁcally the
census tract level estimates for percent of the population older
than 25 who are high school graduates and median income, in
order to determine whether adjustments for these characteristics
altered our ﬁndings [28]. All data were aggregated to the census
tract level. Data collection was approved by the Emory University
Institutional Review Board, the Winship Cancer Institute Clinical
and Translational Review Committee, and the Georgia Department
of Public Health Institutional Review Board.
2.1. Georgia Comprehensive Cancer Registry Data
From 1999 to 2008, the GCCR identiﬁed 12,716 NHL cases
among adults 20 years of age living in Georgia at the time of
diagnosis, of which 11,355 were successfully geocoded. Gender,
race, and age-speciﬁc national NHL rates were obtained using data
from SEER*Stat Version 7.05 [30]. Based on the demographic
structure of each tract, we estimated the expected number of cases
for each tract using these incidence rates. Thirty-two cases (0.28%)
without gender, race, or age were excluded from further analysis.
Lymphoma subgroups and subtypes were deﬁned using ICD-O-3
codes based on the proposed World Health Organization-based
nested classiﬁcation of malignant lymphoid neoplasms for
epidemiologic research from the International Lymphoma Epide-
miology Consortium (InterLymph) [31].
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Facilities are required by the EPA to report their releases for
certain toxic chemicals if they meet thresholds deﬁned by
Section 313 of the Emergency Planning and Community Right-
to-Know Act: namely, if a facility is in a speciﬁc industry sector,
employs 10 or more full-time equivalent employees, and
manufactures or processes more than 25,000 pounds (11,500 kg)
of a TRI-listed chemical or otherwise uses more than 10,000
pounds (4500 kg) of a listed chemical in a given year [32]. Release
information included geographic coordinates of the release site,
amount of on-site disposal or other release, mode of release (e.g.,
total air emissions, surface water discharges, etc.), and year of
release [33]. The output “Total On-site Disposal or Other Releases”
was used as the amount of on-site release for each site. For
benzene, the amount of surface water discharge across all sites was
negligible. From 1989 to 2003, 22 facilities in Georgia reported
some disposal or release of benzene, including 3 facilities reporting
benzene releases for all 15 years. The total amount of benzene
released for each facility ranged from 10 kg to 1.48 million kg over
this time frame.
3. Statistical methods
3.1. Exposure estimation—distance decay
We assumed that amount of benzene exposure was inversely
proportional to the distance from benzene release point sources.
We utilized an exponential decay function commonly used for
estimating decreasing amount of exposure with increasing
distance from a point source, in which the rate of decay is
mitigated by a scaling factor that controls how gradually or quickly
the decay occurs. With this approach, the contribution of a site to
the estimated total passive benzene exposure in a census tract
decreases with increasing distance from that site. We also assumed
that the amount of exposure for a census tract due to benzene
release from a toxic release site, independent of other sites, was
related to the total amount of release from that site during the time
period examined. The total amount of exposure for a census tract
was deﬁned as the cumulative exposure for that region from all
sites with releases during that period.
Thus, we deﬁned the exposure decay function as:
xi ¼
X
j
Rjexp
dij
b
 Fig. 2. Standardized incidence ratios for non-Hodgkin lymphoma, Georgia (left)
and metro Atlanta (right).where xi is the cumulative amount of exposure for tract i,Rj is the
amount of toxic release at release site j, dij is the distance between
the centroid of tract i and location of release site j, and b is the
scaling factor. Distance dij was calculated based on the haversine
formula [34] for measuring great-circle distances from latitudinal
and longitudinal coordinates. Thus, xi represents the total exposure
for a tract from all contributing release sites in the state as a
function of distance from the release site and amount of release
from the site during the period under consideration.
Exposure was then categorized into a discrete variable for
analysis. A 5-level exposure variable was created using quintiles,
with 5 equal-sized data subsets. Scaling factors of 4 km, 8 km,
16 km, and 24 km were explored in order to determine whether the
chosen scaling factor inﬂuenced the relationship between expo-
sure and disease risk. The scaling factor describes a characteristic
distance for “change” in the exposure factor, and represents the
distance over which the exposure associated with a given source
will change by a factor of 1/e. A large characteristic distance
suggests that the exposure decreases slowly with distance
resulting in a longer inﬂuence of each site on exposure and,
potentially, inﬂuence of a greater number of sites on exposure at
any given location. The distance decay function is illustrated in
Fig. 1. Since the appropriate lag time between exposure to benzene
and onset of lymphoma remains unknown [27,35], four separate
exposure periods prior to and overlapping the case data time frame
of 1999–2008 were also examined to identify the exposure period
and scaling factor characteristics that best predicted NHL risk
within our models: 1989–1998, 1989–1993, 1994–1998, 1994–
2003.
3.2. Statistical models
Poisson regression is a commonly used approach for modeling
the relationship between count data and a variable of interest,
particularly for studies with smaller areal units and rare diseases
[36]. Using Poisson regression, we model the number of NHL cases
as a function of exposure level, while ﬁtting an offset, the expected
number of cases in each tract, determined by the age, sex, and race
demographics of the population following our previously pub-
lished methods [27]. In addition to accounting for age, race, and
gender in our model, the expected count represents a measure of
population in each census tract. Thus, even though census tracts
are intended to be approximately the same population, we account
for variability in tract population sizes. The quantity of interest is
the standardized incidence ratio (SIR), the ratio between the
observed number of cases in the tract based on GCCR data and the
expected number of cases, which provides a measure of risk. Risk
ratios were estimated by exponentiating the model parameter
estimates. Additionally, we ﬁt NHL risk as a function of exposure,
while adjusting for percent of the population 25 years and older
who are high school graduates and median income at the census
tract level.
One drawback to a Poisson model is the restriction that the
mean must equal the variance in the count distribution. An
alternative approach for risk estimation allows for overdispersion
(i.e., greater variability in the data than expected from a Poisson
model) via negative binomial regression. Negative binomial
models allow for maximum likelihood estimation of an additional
shape parameter, which provides ﬂexibility for estimating the
variance as distinct from the mean. Because of the potential high
variability in sample size and risk across census tracts, we
constructed Poisson regression and negative binomial regression
models and compared the goodness-of-ﬁt for each approach. This
analysis was also repeated for two NHL subtypes, diffuse large B-
cell lymphoma (DLBCL) and follicular lymphoma (FL).
Table 1
Model goodness-of-ﬁt statistics for prediction of non-Hodgkin lymphoma risk.
Model Exposure period (Years) Scaling factor (km) Deviance/df AIC
Negative binomial 1989–1993 4 1.16 7923.7
Negative binomial 1989–1993 8 1.16 7939.0
Negative binomial 1989–1993 16 1.16 7961.4
Negative binomial 1989–1993 24 1.17 7986.8
Negative binomial 1989–1998 4 1.17 7973.7
Negative binomial 1989–1998 8 1.17 7974.2
Negative binomial 1989–1998 16 1.17 8007.5
Negative binomial 1989–1998 24 1.18 8021.4
Negative binomial 1994–1998 4 1.17 7981.7
Negative binomial 1994–1998 8 1.17 7985.5
Negative binomial 1994–1998 16 1.17 8010.5
Negative binomial 1994–1998 24 1.16 7968.6
Negative binomial 1994–2003 4 1.17 7997.3
Negative binomial 1994–2003 8 1.17 7985.3
Negative binomial 1994–2003 16 1.18 7998.3
Negative binomial 1994–2003 24 1.18 8003.4
Poisson 1989–1993 4 1.60 8058.5
Poisson 1989–1993 8 1.61 8079.8
Poisson 1989–1993 16 1.63 8111.7
Poisson 1989–1993 24 1.65 8143.4
Poisson 1989–1998 4 1.64 8120.7
Poisson 1989–1998 8 1.63 8117.4
Poisson 1989–1998 16 1.67 8169.8
Poisson 1989–1998 24 1.68 8190.1
Poisson 1994–1998 4 1.64 8134.8
Poisson 1994–1998 8 1.65 8137.1
Poisson 1994–1998 16 1.67 8180.0
Poisson 1994–1998 24 1.64 8122.8
Poisson 1994–2003 4 1.66 8156.4
Poisson 1994–2003 8 1.65 8136.0
Poisson 1994–2003 16 1.65 8151.4
Poisson 1994–2003 24 1.66 8166.5
Fig. 3. Negative binomial model risk ratios, using Level 1 as the reference level.
Lines are color-coded by exposure period: 1989–1993 (black), 1989–1998 (red),
1994–1998 (blue), 1994–2003 (green). Line type indicates scaling factor.
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Goodness-of-ﬁt for both the Poisson and negative binomial
models was assessed using the residual deviance divided by the
degrees of freedom (df). AIC values were reported in order to
compare the relative ﬁts of the Poisson and negative binomial
models at various scaling factors and exposure periods. Plots of
observed vs. expected values provided additional assessment of
model ﬁt for each observation to check for high leverage and/or
inﬂuential observations.
Risk ratios and conﬁdence intervals (CI) were reported.
Signiﬁcance was assessed at the p < 0.05 level, and statistical
analysis was performed using R 2.15.1 [37] (R Statistical Comput-
ing, Vienna, Austria). A Bonferroni approach was further explored
to control for Type I error given the high number of hypothesis
tests, with 128 total pairwise tests for both Poisson and negative
binomial regression techniques combined. The R package glm.nb
[38] was used for estimating negative binomial model parameters
when the shape parameter was unknown. Census tract shapeﬁles
were uploaded to R using the package maptools [39], and we
observed and plotted the spatial distributions of benzene exposure
levels along with the SIRs for NHL.
4. Results
11,323 NHL cases with available demographic information were
geocoded across 1616 tracts in Georgia from 1999 to 2008, yielding
an average of 7.0 NHL cases per tract (minimum: 0, 25th percentile:
3, median: 6, 75th percentile: 10, maximum: 47). Of the 22 benzene
TRI release sites in Georgia from 1989 to 2003, 7 facilities reported
benzene released from 1989 to 1993, 18 facilities reported benzene
released from 1989 to 1998, 16 facilities reported benzene released
from 1994 to 1998, and 19 facilities reported benzene released
from 1994 to 2003. The average number of years that a facilityreported benzene release from 1989 to 2003 was 6.2 years.
Cumulative exposure levels were categorized into quintiles.
The map of observed SIRs for each Georgia census tract for NHL
is shown in Fig. 2. Elevated risk was concentrated in the metro
Atlanta area, deﬁned as Fulton, DeKalb, Clayton, Cobb, and
Gwinnett counties, as well as some rural census tracts, indicated
by the darker shades. Previous analyses of NHL incidence based on
these data using Moran’s I, a measure of spatial autocorrelation,
yielded evidence of signiﬁcant global spatial correlation [27].
Table 2
Negative binomial regression statistics for the 1989–1993 and the 1989–1998 exposure periods.
Exposure period (Years) Scaling factor (km) Effect Level (in kg) Risk ratio 95% CI p-value
1989–1993 4 Exposure: Level 2 vs. Level 1 [2.4e-12–3.5e-06] vs. [7.3e-33–2.4e-12] 1.22 (1.12, 1.32) <0.0001
Exposure: Level 3 vs. Level 1 [3.5e-06–1.1] vs. [7.3e-33–2.4e-12] 1.40 (1.30, 1.52) <0.0001
Exposure: Level 4 vs. Level 1 [1.1–160] vs. [7.3e-33–2.4e-12] 1.56 (1.44, 1.68) <0.0001
Exposure: Level 5 vs. Level 1 [160–360,000] vs. [7.3e-33–2.4e-12] 1.60 (1.48, 1.74) <0.0001
1989–1993 8 Exposure: Level 2 vs. Level 1 [0.00015–0.15] vs. [6.9e-15–0.00015] 1.20 (1.11, 1.30) <0.0001
Exposure: Level 3 vs. Level 1 [0.15–78] vs. [6.9e-15–0.00015] 1.39 (1.29, 1.50) <0.0001
Exposure: Level 4 vs. Level 1 [78–710] vs. [6.9e-15–0.00015] 1.50 (1.39, 1.63) <0.0001
Exposure: Level 5 vs. Level 1 [710–570,000] vs. [6.9e-15–0.00015] 1.58 (1.46, 1.71) <0.0001
1989–1993 16 Exposure: Level 2 vs. Level 1 [1.9–86] vs. [2.4e-05–1.9] 1.11 (1.03, 1.21) 0.0086
Exposure: Level 3 vs. Level 1 [86–720] vs. [2.4e-05–1.9] 1.37 (1.27, 1.48) <0.0001
Exposure: Level 4 vs. Level 1 [720–2000] vs. [2.4e-05–1.9] 1.44 (1.34, 1.56) <0.0001
Exposure: Level 5 vs. Level 1 [2000–720,000] vs. [2.4e-05–1.9] 1.46 (1.35, 1.58) <0.0001
1989–1993 24 Exposure: Level 2 vs. Level 1 [55–740] vs. [0.072–55] 1.05 (0.97, 1.14) 0.1997
Exposure: Level 3 vs. Level 1 [740–2000] vs. [0.072–55] 1.38 (1.28, 1.49) <0.0001
Exposure: Level 4 vs. Level 1 [2000–3400] vs. [0.072–55] 1.35 (1.25, 1.45) <0.0001
Exposure: Level 5 vs. Level 1 [3400–770,000] vs. [0.072–55] 1.30 (1.20, 1.41) <0.0001
1989–1998 4 Exposure: Level 2 vs. Level 1 [1.2e-06–0.0082] vs. [3.3e-17–1.2e-06] 1.02 (0.95, 1.11) 0.5591
Exposure: Level 3 vs. Level 1 [0.0082–14] vs. [3.3e-17–1.2e-06] 1.33 (1.24, 1.43) <0.0001
Exposure: Level 4 vs. Level 1 [14–370] vs. [3.3e-17–1.2e-06] 1.35 (1.26, 1.46) <0.0001
Exposure: Level 5 vs. Level 1 [370–560,000] vs. [3.3e-17–1.2e-06] 1.36 (1.26, 1.47) <0.0001
1989–1998 8 Exposure: Level 2 vs. Level 1 [0.056–7.6] vs. [8.7e-07–0.056] 1.09 (1.00, 1.17) 0.0408
Exposure: Level 3 vs. Level 1 [7.6–280] vs. [8.7e-07–0.056] 1.38 (1.28, 1.48) <0.0001
Exposure: Level 4 vs. Level 1 [280–1400] vs. [8.7e-07–0.056] 1.39 (1.29, 1.50) <0.0001
Exposure: Level 5 vs. Level 1 [1400–890,000] vs. [8.7e-07–0.056] 1.37 (1.27, 1.49) <0.0001
1989–1998 16 Exposure: Level 2 vs. Level 1 [39–350] vs. [0.12–39] 1.22 (1.13, 1.31) <0.0001
Exposure: Level 3 vs. Level 1 [350–1700] vs. [0.12–39] 1.37 (1.27, 1.48) <0.0001
Exposure: Level 4 vs. Level 1 [1700–3500] vs. [0.12–39] 1.41 (1.30, 1.52) <0.0001
Exposure: Level 5 vs. Level 1 [3500–1,100,000] vs. [0.12–39] 1.32 (1.22, 1.43) <0.0001
1989–1998 24 Exposure: Level 2 vs. Level 1 [530–2300] vs. [4.2–530] 1.23 (1.14, 1.33) <0.0001
Exposure: Level 3 vs. Level 1 [2300–3900] vs. [4.2–530] 1.33 (1.23, 1.43) <0.0001
Exposure: Level 4 vs. Level 1 [3900–5600] vs. [4.2–530] 1.34 (1.24, 1.45) <0.0001
Exposure: Level 5 vs. Level 1 [5600–1,200,000] vs. [4.2–530] 1.10 (1.02, 1.19) 0.0211
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binomial parameterizations used for 4 different spatial scaling
factors and 4 different time frames for exposure accumulation.
Model ﬁt criteria are displayed in Table 1. Based on the deviance/df
criteria for goodness-of-ﬁt, the Poisson models demonstrated poor
ﬁt. The negative binomial models demonstrated much better ﬁt
with all deviance/df values near 1. Consequently, the following
results are drawn from the negative binomial models.
Risk ratios for all negative binomial models are displayed in
Fig. 3, using the lowest exposure level as the reference. In nearly
every model, lymphoma risk increased as the level of exposure
increased, particularly for the three highest levels of exposure in
comparison to the lowest level. Sixty-three of the 64 risk ratios
(from 16 total models) comparing an upper level of exposure to the
lowest level were above the null value of 1. Fifty-eight of the 64 95%
CIs did not contain the null value of 1, and of the remaining 6,
5 resulted from a comparison of Level 2 (the 2nd lowest level) vs.
Level 1 (Tables 2 and 3). Using a conservative Bonferroni approach
for allocating Type I error, 54 of the 64 hypothesis tests yielded p-
values below 0.05/128 (threshold = 0.00039).
The exposure period of 1989–1993 with the smallest scaling
factor of 4 km yielded the lowest AIC value for NHL. Moreover, a
scaling factor of 4 km provided the lowest AIC value for the 1989–
1998 exposure period, while scaling factors of 24 km and 8 km
produced the lowest AIC values for the 1994–1998 and 1994–
2003 exposure periods, respectively. For the scaling factors of 4 km,8 km, and 16 km, the exposure period of 1989–1993 produced the
lowest AIC values, while for the scaling factor of 24 km, the 1994–
1998 exposure period produced the lowest AIC value. Thus, the
exposure periods that included the oldest exposure data were
better ﬁt with smaller scaling factors, yielding a stronger local
effect. The exposure periods including the more recent exposure
data were better ﬁt with larger scaling factors, yielding a weaker
local effect and a stronger regional effect.
The map of exposure levels for the best ﬁtting model in relation
to location of benzene release sites in that time frame is displayed
in Fig. 4. The highest exposure level census tracts were observed in
the center of metro Atlanta as well as in close proximity to the
Augusta, GA, benzene release site. Risk ratios, 95% CIs, and p-values
for this model are reported in Table 2. In this model, a Level 4 tract
had a 56% higher risk of NHL than a Level 1 tract; likewise, risk was
60% higher in a Level 5 tract vs. a Level 1 tract. In the best ﬁtting
model, when adjusting for SES census tract level variables such as
percent of the population 25 years and older who are high school
graduates and median income, the results remain consistent
where higher exposure levels have higher risk of NHL compared to
the lowest levels (Table 4). For the 4 km scaling factor and exposure
time frame of 1989–1993, the cut points separating exposure levels
1–5 were: 2.4 1012 kg, 3.5 106 kg, 1.1 kg, and 160 kg, with a
minimum exposure of 7.3  1033 kg and a maximum of
360,000 kg. Results for the subtype analysis are reported in
Appendix.
Table 3
Negative binomial regression statistics for the 1994–2003 and the 1994–1998 exposure periods.
Exposure period (Years) Scaling factor (km) Effect Level (in kg) Risk ratio 95% CI p-value
1994–1998 4 Exposure: Level 2 vs. Level 1 [8.2e-07–0.0038] vs. [3.3e-17–8.2e-07] 1.05 (0.97, 1.13) 0.2378
Exposure: Level 3 vs. Level 1 [0.0038–6.4] vs. [3.3e-17–8.2e-07] 1.32 (1.23, 1.42) <0.0001
Exposure: Level 4 vs. Level 1 [6.4–70] vs. [3.3e-17–8.2e-07] 1.40 (1.30, 1.51) <0.0001
Exposure: Level 5 vs. Level 1 [70–200,000] vs. [3.3e-17–8.2e-07] 1.33 (1.23, 1.43) <0.0001
1994–1998 8 Exposure: Level 2 vs. Level 1 [0.037–3.8] vs. [8.7e-07–0.037] 1.09 (1.01, 1.18) 0.0243
Exposure: Level 3 vs. Level 1 [3.8–98] vs. [8.7e-07–0.037] 1.35 (1.26, 1.45) <0.0001
Exposure: Level 4 vs. Level 1 [98–360] vs. [8.7e-07–0.037] 1.42 (1.32, 1.53) <0.0001
Exposure: Level 5 vs. Level 1 [360–320,000] vs. [8.7e-07–0.037] 1.31 (1.21, 1.41) <0.0001
1994–1998 16 Exposure: Level 2 vs. Level 1 [23–160] vs. [0.12–23] 1.25 (1.16, 1.35) <0.0001
Exposure: Level 3 vs. Level 1 [160–630] vs. [0.12–23] 1.36 (1.26, 1.46) <0.0001
Exposure: Level 4 vs. Level 1 [630–1100] vs. [0.12–23] 1.42 (1.31, 1.53) <0.0001
Exposure: Level 5 vs. Level 1 [1100–410,000] vs. [0.12–23] 1.25 (1.16, 1.36) <0.0001
1994–1998 24 Exposure: Level 2 vs. Level 1 [290–1100] vs. [2.2–290] 1.25 (1.17, 1.35) <0.0001
Exposure: Level 3 vs. Level 1 [1100–1600] vs. [2.2–290] 1.30 (1.20, 1.39) <0.0001
Exposure: Level 4 vs. Level 1 [1600–1900] vs. [2.2–290] 1.40 (1.32, 1.53) <0.0001
Exposure: Level 5 vs. Level 1 [1900–440,000] vs. [2.2–290] 0.99 (0.92, 1.07) 0.8065
1994–2003 4 Exposure: Level 2 vs. Level 1 [9.8e-06–0.018] vs. [2e-13–9.8e-06] 1.06 (0.98, 1.15) 0.1532
Exposure: Level 3 vs. Level 1 [0.018–19] vs. [2e-13–9.8e-06] 1.28 (1.19, 1.38) <0.0001
Exposure: Level 4 vs. Level 1 [19–250] vs. [2e-13–9.8e-06] 1.34 (1.24, 1.44) <0.0001
Exposure: Level 5 vs. Level 1 [250–230,000] vs. [2e-13–9.8e-06] 1.37 (1.27, 1.48) <0.0001
1994–2003 8 Exposure: Level 2 vs. Level 1 [0.17–11] vs. [2.9e-05–0.17] 1.03 (0.96, 1.12) 0.3982
Exposure: Level 3 vs. Level 1 [11–270] vs. [2.9e-05–0.17] 1.29 (1.19, 1.38) <0.0001
Exposure: Level 4 vs. Level 1 [270–1300] vs. [2.9e-05–0.17] 1.37 (1.27, 1.48) <0.0001
Exposure: Level 5 vs. Level 1 [1300–370,000] vs. [2.9e-05–0.17] 1.35 (1.25, 1.45) <0.0001
1994–2003 16 Exposure: Level 2 vs. Level 1 [56–370] vs. [0.17–56] 1.19 (1.11, 1.29) <0.0001
Exposure: Level 3 vs. Level 1 [370–1600] vs. [0.17–56] 1.28 (1.19, 1.38) <0.0001
Exposure: Level 4 vs. Level 1 [1600–3900] vs. [0.17–56] 1.47 (1.36, 1.58) <0.0001
Exposure: Level 5 vs. Level 1 [3900–460,000] vs. [0.17–56] 1.32 (1.22, 1.42) <0.0001
1994–2003 24 Exposure: Level 2 vs. Level 1 [570–1800] vs. [3.9–570] 1.18 (1.09, 1.27) <0.0001
Exposure: Level 3 vs. Level 1 [1800–4100] vs. [3.9–570] 1.38 (1.29, 1.49) <0.0001
Exposure: Level 4 vs. Level 1 [4100–6200] vs. [3.9–570] 1.40 (1.30, 1.51) <0.0001
Exposure: Level 5 vs. Level 1 [6200–500,000] vs. [3.9–570] 1.21 (1.12, 1.31) <0.0001
Fig. 4. Locations of benzene release sites in Georgia and exposure levels from 1989
to 1993, with a scaling factor of 4 km. This exposure period and scaling factor
produced the lowest AIC value. Cumulative exposure was categorized into 5 levels
based on quintiles. Census tracts are color-coded according to exposure level, where
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This study extends our existing understanding of the relation-
ship between proximity to benzene release sites and NHL risk by
utilizing TRI data to weight our measure of exposure by both
proximity to release sites and amount of release. In addition, we
utilized a method for estimating the level of benzene exposure in a
given geographic space and ﬁt statistical models to examine
associations between exposure periods, lag times, and lymphoma
incident cases. For all models, we evaluated the goodness-of-ﬁt
and assessed the optimal scaling factor parameter to measure
exposure in addition to the effects of time lag variations on
goodness-of-ﬁt.
Across our models, we consistently found that census tracts
that were considered higher-exposure zones exhibited higher risk
of NHL than lower-exposure zones, and that a statistically
signiﬁcant effect was noted even at very low exposure levels—
far below occupational exposure levels. This consistency across
conditions suggests that the effect of passive benzene exposure on
lymphoma risk was independent of both time lag and scaling
factor. Although the results are similar to our previous ﬁndings
[27], the added magnitude component strengthens the argument
that passive exposure is associated with NHL risk, not only as a
result of distance from release sites, but also as a function of
amount of benzene released from these facilities over time.
Other studies have demonstrated that occupational exposure to
benzene even in low doses increases cancer risk [2,3]. In addition,the darkest blue represents the highest level of exposure.
Table 4
Negative binomial regression statistics for the 1989–1993 exposure period and 4-km scaling factor adjusting for percent of the population 25 years and older who are high
school graduates and median income.
Exposure period (Years) Scaling factor (km) Effect Level (in kg) Risk ratio 95% CI p-value
1989–1993 4 Exposure: Level 2 vs. Level 1 [8.2e-07–0.0038] vs. [3.3e-17–8.2e-07] 1.18 (1.04, 1.33) 0.0124
Exposure: Level 3 vs. Level 1 [0.0038–6.4] vs. [3.3e-17–8.2e-07] 1.30 (1.15, 1.47) <0.0001
Exposure: Level 4 vs. Level 1 [6.4–70] vs. [3.3e-17–8.2e-07] 1.27 (1.12, 1.45) 0.0004
Exposure: Level 5 vs. Level 1 [70–200,000] vs. [3.3e-17–8.2e-07] 1.50 (1.32, 1.71) <0.0001
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demonstrate that passive exposure through residential proximity
to EPA-identiﬁed benzene release sites is associated with increased
risk of NHL [27]. In this current study, we used amount of release
and coordinate data extracted from the EPA’s TRI to expand upon
this ﬁnding and utilized a method for quantifying the level of
passive benzene exposure based on proximity to each site and
amount of release. We further tested this method using varying
spatial scaling factors and exposure periods to assess for different
assumed time lags between exposure and disease. It is not known
how quickly or broadly benzene dissipates in the atmosphere from
these release sites, nor is it known exactly how quickly lymphoma
develops in the setting of long-term passive exposure to benzene.
As a result, using several scaling factors and lag times enabled us to
assess how consistent our results were under reasonable, varying
conditions.
Limitations of this study include the use of retrospective data to
assess the impact of benzene exposure on cancer risk. Despite the
use of varying lag times for exposure and onset of cases, our results
indicate only an association between exposure and disease, rather
than a causative effect. In addition, data were aggregated at the
census tract level in order to capture the spatial association
between proximity to release sites and cancer risk; as a result, we
should be cautious in extrapolating these ﬁndings to the individual
level, since environmental exposure does not necessarily equate to
individual exposure. Furthermore, by aggregating to the census
tract level, we encountered census tracts of various geographic
sizes, which could lead to worse exposure classiﬁcation in larger
sized tracts with smaller populations when utilizing smaller
scaling factors. Additionally, other sources of benzene such as
occupational and trafﬁc sources were not characterized in this
aggregated analysis; however, this type of analysis was exploratory
and provides hypothesis-generating results for subsequent studies
involving patient-level data.
We also recognize that the exposure cut points for the best
ﬁtting model were very small (<1 kg for the 20th and 40th
percentile), and it could be argued that lower exposure levels for
smaller scaling factors should be grouped. However, for the
purposes of consistency across scaling factors and exposure
periods, we kept the number of quantiles at 5 for all models. It
also should be noted that the risk ratio between Levels 1 and
2 exposure levels was not statistically signiﬁcant for several scaling
factors and exposure periods, which further supports a strategy of
grouping exposure levels with small differences in cumulative
exposure.
Future analyses could include more advanced statistical models
for isolating the effect of benzene exposure on cancer risk, such as
spatial Bayesian hierarchical models with conditionally autore-
gressive random effects [40–42]. These types of models attempt to
classify observed correlated data, such as spatial data, and control
for other potential unmeasured confounding risk factors. Such
models also provide more precise incidence estimates for small
areas with lower observed case numbers, which often yield
inﬂated rate and ratio estimates if left unadjusted.
Despite the use of several spatial scaling factors in our models
as a measure of model sensitivity, we could not pinpoint theprecise dispersion of benzene from these sites over time, and we
found that only 9.5% of census tracts remained in the same
exposure level across all 4 scaling factors and 4 exposure periods.
Thus, future work could include identifying more precisely the
benzene dispersion/scaling parameter from a release site. In order
to isolate the true exposure effect on disease risk in an aggregated
spatial analysis and to reduce the spatial uncertainty from varying
scaling factors, it is necessary to estimate the rate at which
benzene diffuses into the atmosphere surrounding these sites. It is
likely that the diffusion would be inﬂuenced by meteorological
data, such as wind speeds and direction. Collecting observational
benzene exposure data around release sites at varying distances
over time in order to estimate the benzene dispersion parameter
may further reduce spatial uncertainty in estimations of exposure
using this approach. Subsequent investigation of the effects of
passive benzene exposure on cancer risk should also involve
individual patient-level data in the form of a case-control study or
other longitudinal observational study where benzene levels can
be monitored at the individual exposure level. We are engaged in
ongoing studies measuring BTEX releases at various distances
around TRI sites and assessing patient-level risk factors for
individuals with NHL in Georgia. Upcoming goals of our research
in this area aim to improve our understanding of the interactions
between long-term passive exposure to VOCs and clinical, lifestyle,
and genetic factors that contribute to cancer risk for individuals
and populations. Our data provide a foundation for this approach.
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Table A1b
Model goodness-of-ﬁt statistics for prediction of FL risk.
Model Exposure period (Years) Scaling factor (km) Deviance/df AIC
Negative binomial 1989–1993 4 1.05 4359.3
Negative binomial 1989–1993 8 1.05 4364.1
Negative binomial 1989–1993 16 1.05 4358.4
Negative binomial 1989–1993 24 1.05 4364.0
Negative binomial 1989–1998 4 1.06 4369.7
Negative binomial 1989–1998 8 1.06 4357.1
Negative binomial 1989–1998 16 1.05 4362.2
Negative binomial 1989–1998 24 1.05 4363.9
Negative binomial 1994–1998 4 1.06 4376.5
Negative binomial 1994–1998 8 1.06 4374.7
Negative binomial 1994–1998 16 1.05 4373.6
Negative binomial 1994–1998 24 1.05 4347.9
Negative binomial 1994–2003 4 1.06 4382.6
Negative binomial 1994–2003 8 1.06 4381.3
Negative binomial 1994–2003 16 1.06 4373.7
Negative binomial 1994–2003 24 1.05 4377.2
Poisson 1989–1993 4 1.12 4362.8
Poisson 1989–1993 8 1.12 4367.9
Poisson 1989–1993 16 1.12 4361.5
Poisson 1989–1993 24 1.12 4367.5
Poisson 1989–1998 4 1.13 4373.7
Poisson 1989–1998 8 1.12 4359.7
Poisson 1989–1998 16 1.12 4365.8
Poisson 1989–1998 24 1.12 4367.5
Poisson 1994–1998 4 1.13 4380.9
Poisson 1994–1998 8 1.13 4379.1
Poisson 1994–1998 16 1.13 4378.5
Poisson 1994–1998 24 1.11 4350.1
Poisson 1994–2003 4 1.14 4387.7
Poisson 1994–2003 8 1.13 4385.6
Poisson 1994–2003 16 1.13 4377.8
Poisson 1994–2003 24 1.13 4382.2
Table A1a
Model goodness-of-ﬁt statistics for prediction of DLBCL risk.
Model Exposure period (Years) Scaling factor (km) Deviance/df AIC
Negative binomial 1989–1993 4 1.13 5656.1
Negative binomial 1989–1993 8 1.14 5657.9
Negative binomial 1989–1993 16 1.14 5674.8
Negative binomial 1989–1993 24 1.14 5683.0
Negative binomial 1989–1998 4 1.14 5674.2
Negative binomial 1989–1998 8 1.14 5671.6
Negative binomial 1989–1998 16 1.14 5687.1
Negative binomial 1989–1998 24 1.14 5700.2
Negative binomial 1994–1998 4 1.14 5683.5
Negative binomial 1994–1998 8 1.14 5683.3
Negative binomial 1994–1998 16 1.14 5683.6
Negative binomial 1994–1998 24 1.13 5666.1
Negative binomial 1994–2003 4 1.14 5682.6
Negative binomial 1994–2003 8 1.14 5678.1
Negative binomial 1994–2003 16 1.15 5681.8
Negative binomial 1994–2003 24 1.14 5681.4
Poisson 1989–1993 4 1.31 5680.7
Poisson 1989–1993 8 1.31 5682.3
Poisson 1989–1993 16 1.32 5701.9
Poisson 1989–1993 24 1.33 5711.1
Poisson 1989–1998 4 1.32 5700.0
Poisson 1989–1998 8 1.32 5696.5
Poisson 1989–1998 16 1.33 5714.8
Poisson 1989–1998 24 1.34 5730.4
Poisson 1994–1998 4 1.33 5710.9
Poisson 1994–1998 8 1.33 5710.0
Poisson 1994–1998 16 1.33 5711.4
Poisson 1994–1998 24 1.32 5693.2
Poisson 1994–2003 4 1.33 5709.7
Poisson 1994–2003 8 1.33 5703.3
Poisson 1994–2003 16 1.33 5706.0
Poisson 1994–2003 24 1.33 5707.3
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Table A2a
Negative binomial regression statistics for the 1989–1993 and the 1989–1998 exposure periods – DLBCL.
Exposure period (Years) Scaling factor (km) Effect Level (in kg) Risk ratio 95% CI p-value
1989–1993 4 Exposure: Level 2 vs. Level 1 [2.4e-12–3.5e-06] vs. [7.3e-33–2.4e-12] 1.18 (1.04, 1.34) 0.0099
Exposure: Level 3 vs. Level 1 [3.5e-06–1.1] vs. [7.3e-33–2.4e-12] 1.36 (1.20, 1.53) <0.0001
Exposure: Level 4 vs. Level 1 [1.1–160] vs. [7.3e-33–2.4e-12] 1.49 (1.32, 1.67) <0.0001
Exposure: Level 5 vs. Level 1 [160–360,000] vs. [7.3e-33–2.4e-12] 1.66 (1.46, 1.88) <0.0001
1989–1993 8 Exposure: Level 2 vs. Level 1 [0.00015–0.15] vs. [6.9e-15–0.00015] 1.21 (1.06, 1.37) 0.0035
Exposure: Level 3 vs. Level 1 [0.15–78] vs. [6.9e-15–0.00015] 1.37 (1.21, 1.54) <0.0001
Exposure: Level 4 vs. Level 1 [78–710] vs. [6.9e-15–0.00015] 1.51 (1.34, 1.70) <0.0001
Exposure: Level 5 vs. Level 1 [710–570,000] vs. [6.9e-15–0.00015] 1.65 (1.46, 1.87) <0.0001
1989–1993 16 Exposure: Level 2 vs. Level 1 [1.9–86] vs. [2.4e-05–1.9] 1.09 (0.96, 1.23) 0.1892
Exposure: Level 3 vs. Level 1 [86–720] vs. [2.4e-05–1.9] 1.33 (1.18, 1.49) <0.0001
Exposure: Level 4 vs. Level 1 [720–2000] vs. [2.4e-05–1.9] 1.38 (1.23, 1.56) <0.0001
Exposure: Level 5 vs. Level 1 [2000–720,000] vs. [2.4e-05–1.9] 1.49 (1.32, 1.69) <0.0001
1989–1993 24 Exposure: Level 2 vs. Level 1 [55–740] vs. [0.072–55] 1.01 (0.89, 1.14) 0.9361
Exposure: Level 3 vs. Level 1 [740–2000] vs. [0.072–55] 1.34 (1.19, 1.50) <0.0001
Exposure: Level 4 vs. Level 1 [2000–3400] vs. [0.072–55] 1.31 (1.16, 1.47) <0.0001
Exposure: Level 5 vs. Level 1 [3400–770,000] vs. [0.072–55] 1.32 (1.17, 1.49) <0.0001
1989–1998 4 Exposure: Level 2 vs. Level 1 [1.2e-06–0.0082] vs. [3.3e-17–1.2e-06] 1.00 (0.89, 1.13) 0.9589
Exposure: Level 3 vs. Level 1 [0.0082–14] vs. [3.3e-17–1.2e-06] 1.28 (1.14, 1.43) <0.0001
Exposure: Level 4 vs. Level 1 [14–370] vs. [3.3e-17–1.2e-06] 1.32 (1.18, 1.48) <0.0001
Exposure: Level 5 vs. Level 1 [370–560,000] vs. [3.3e-17–1.2e-06] 1.44 (1.28, 1.62) <0.0001
1989–1998 8 Exposure: Level 2 vs. Level 1 [0.056–7.6] vs. [8.7e-07–0.056] 1.13 (1.00, 1.27) 0.0483
Exposure: Level 3 vs. Level 1 [7.6–280] vs. [8.7e-07–0.056] 1.36 (1.21, 1.52) <0.0001
Exposure: Level 4 vs. Level 1 [280–1400] vs. [8.7e-07–0.056] 1.41 (1.26, 1.58) <0.0001
Exposure: Level 5 vs. Level 1 [1400–890,000] vs. [8.7e-07–0.056] 1.52 (1.35, 1.71) <0.0001
1989–1998 16 Exposure: Level 2 vs. Level 1 [39–350] vs. [0.12–39] 1.26 (1.12, 1.42) 0.0002
Exposure: Level 3 vs. Level 1 [350–1700] vs. [0.12–39] 1.35 (1.21, 1.52) <0.0001
Exposure: Level 4 vs. Level 1 [1700–3500] vs. [0.12–39] 1.43 (1.28, 1.61) <0.0001
Exposure: Level 5 vs. Level 1 [3500–1,100,000] vs. [0.12–39] 1.45 (1.28, 1.63) <0.0001
1989–1998 24 Exposure: Level 2 vs. Level 1 [530–2300] vs. [4.2–530] 1.26 (1.13, 1.41) 0.0001
Exposure: Level 3 vs. Level 1 [2300–3900] vs. [4.2–530] 1.32 (1.18, 1.48) <0.0001
Exposure: Level 4 vs. Level 1 [3900–5600] vs. [4.2–530] 1.37 (1.23, 1.54) <0.0001
Exposure: Level 5 vs. Level 1 [5600–1,200,000] vs. [4.2–530] 1.15 (1.02, 1.31) 0.0239
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Table A2b
Negative binomial regression statistics for the 1989–1993 and the 1989–1998 exposure periods – FL.
Exposure period (Years) Scaling factor (km) Effect Level (in kg) Risk ratio 95% CI p-value
1989–1993 4 Exposure: Level 2 vs. Level 1 [2.4e-12–3.5e-06] vs. [7.3e-33–2.4e-12] 1.29 (1.10, 1.51) 0.0016
Exposure: Level 3 vs. Level 1 [3.5e-06–1.1] vs. [7.3e-33–2.4e-12] 1.41 (1.21, 1.65) <0.0001
Exposure: Level 4 vs. Level 1 [1.1–160] vs. [7.3e-33–2.4e-12] 1.57 (1.35, 1.83) <0.0001
Exposure: Level 5 vs. Level 1 [160–360,000] vs. [7.3e-33–2.4e-12] 1.22 (1.03, 1.45) 0.022
1989–1993 8 Exposure: Level 2 vs. Level 1 [0.00015–0.15] vs. [6.9e-15–0.00015] 1.25 (1.07, 1.47) 0.0048
Exposure: Level 3 vs. Level 1 [0.15–78] vs. [6.9e-15–0.00015] 1.38 (1.19, 1.61) <0.0001
Exposure: Level 4 vs. Level 1 [78–710] vs. [6.9e-15–0.00015] 1.51 (1.30, 1.76) <0.0001
Exposure: Level 5 vs. Level 1 [710–570,000] vs. [6.9e-15–0.00015] 1.17 (0.99, 1.39) 0.0611
1989–1993 16 Exposure: Level 2 vs. Level 1 [1.9–86] vs. [2.4e-05–1.9] 1.22 (1.05, 1.43) 0.0118
Exposure: Level 3 vs. Level 1 [86–720] vs. [2.4e-05–1.9] 1.45 (1.25, 1.68) <0.0001
Exposure: Level 4 vs. Level 1 [720–2000] vs. [2.4e-05–1.9] 1.50 (1.29, 1.75) <0.0001
Exposure: Level 5 vs. Level 1 [2000–720,000] vs. [2.4e-05–1.9] 1.14 (0.97, 1.35) 0.1194
1989–1993 24 Exposure: Level 2 vs. Level 1 [55–740] vs. [0.072–55] 1.17 (1.01, 1.36) 0.0378
Exposure: Level 3 vs. Level 1 [740–2000] vs. [0.072–55] 1.39 (1.21, 1.61) <0.0001
Exposure: Level 4 vs. Level 1 [2000–3400] vs. [0.072–55] 1.38 (1.19, 1.60) <0.0001
Exposure: Level 5 vs. Level 1 [3400–770,000] vs. [0.072–55] 1.03 (0.88, 1.22) 0.6924
1989–1998 4 Exposure: Level 2 vs. Level 1 [1.2e-06–0.0082] vs. [3.3e-17–1.2e-06] 0.95 (0.82, 1.10) 0.4982
Exposure: Level 3 vs. Level 1 [0.0082–14] vs. [3.3e-17–1.2e-06] 1.25 (1.10, 1.43) 0.0009
Exposure: Level 4 vs. Level 1 [14–370] vs. [3.3e-17–1.2e-06] 1.23 (1.07, 1.41) 0.0029
Exposure: Level 5 vs. Level 1 [370–560,000] vs. [3.3e-17–1.2e-06] 0.96 (0.82, 1.13) 0.6264
1989–1998 8 Exposure: Level 2 vs. Level 1 [0.056–7.6] vs. [8.7e-07–0.056] 1.07 (0.93, 1.24) 0.3576
Exposure: Level 3 vs. Level 1 [7.6–280] vs. [8.7e-07–0.056] 1.33 (1.16, 1.51) <0.0001
Exposure: Level 4 vs. Level 1 [280–1400] vs. [8.7e-07–0.056] 1.32 (1.15, 1.52) 0.0001
Exposure: Level 5 vs. Level 1 [1400–890,000] vs. [8.7e-07–0.056] 0.91 (0.77, 1.07) 0.2623
1989–1998 16 Exposure: Level 2 vs. Level 1 [39–350] vs. [0.12–39] 1.22 (1.06, 1.40) 0.0067
Exposure: Level 3 vs. Level 1 [350–1700] vs. [0.12–39] 1.29 (1.12, 1.47) 0.0003
Exposure: Level 4 vs. Level 1 [1700–3500] vs. [0.12–39] 1.33 (1.15, 1.53) 0.0001
Exposure: Level 5 vs. Level 1 [3500–1,100,000] vs. [0.12–39] 0.91 (0.77, 1.07) 0.2506
1989–1998 24 Exposure: Level 2 vs. Level 1 [530–2300] vs. [4.2–530] 1.24 (1.08, 1.42) 0.0018
Exposure: Level 3 vs. Level 1 [2300–3900] vs. [4.2–530] 1.24 (1.08, 1.42) 0.0023
Exposure: Level 4 vs. Level 1 [3900–5600] vs. [4.2–530] 1.17 (1.02, 1.35) 0.0283
Exposure: Level 5 vs. Level 1 [5600–1,200,000] vs. [4.2–530] 0.84 (0.71, 0.99) 0.039
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Table A3a
Negative binomial regression statistics for the 1994–2003 and the 1994–1998 exposure periods - DLBCL.
Exposure period (Years) Scaling factor (km) Effect Level (in kg) Risk ratio 95% CI p-value
1994–1998 4 Exposure: Level 2 vs. Level 1 [8.2e-07–0.0038] vs. [3.3e-17–8.2e-07] 1.03 (0.91, 1.16) 0.6273
Exposure: Level 3 vs. Level 1 [0.0038–6.4] vs. [3.3e-17–8.2e-07] 1.28 (1.14, 1.43) <0.0001
Exposure: Level 4 vs. Level 1 [6.4–70] vs. [3.3e-17–8.2e-07] 1.38 (1.23, 1.55) <0.0001
Exposure: Level 5 vs. Level 1 [70–200,000] vs. [3.3e-17–8.2e-07] 1.34 (1.20, 1.51) <0.0001
1994–1998 8 Exposure: Level 2 vs. Level 1 [0.037–3.8] vs. [8.7e-07–0.037] 1.12 (1.00, 1.27) 0.0546
Exposure: Level 3 vs. Level 1 [3.8–98] vs. [8.7e-07–0.037] 1.33 (1.19, 1.49) <0.0001
Exposure: Level 4 vs. Level 1 [98–360] vs. [8.7e-07–0.037] 1.44 (1.28, 1.62) <0.0001
Exposure: Level 5 vs. Level 1 [360–320,000] vs. [8.7e-07–0.037] 1.37 (1.22, 1.54) <0.0001
1994–1998 16 Exposure: Level 2 vs. Level 1 [23–160] vs. [0.12–23] 1.29 (1.15, 1.45) <0.0001
Exposure: Level 3 vs. Level 1 [160–630] vs. [0.12–23] 1.35 (1.20, 1.51) <0.0001
Exposure: Level 4 vs. Level 1 [630–1100] vs. [0.12–23] 1.53 (1.36, 1.71) <0.0001
Exposure: Level 5 vs. Level 1 [1100–410,000] vs. [0.12–23] 1.29 (1.15, 1.45) <0.0001
1994–1998 24 Exposure: Level 2 vs. Level 1 [290–1100] vs. [2.2–290] 1.28 (1.15, 1.43) <0.0001
Exposure: Level 3 vs. Level 1 [1100–1600] vs. [2.2–290] 1.32 (1.18, 1.48) <0.0001
Exposure: Level 4 vs. Level 1 [1600–1900] vs. [2.2–290] 1.49 (1.33, 1.67) <0.0001
Exposure: Level 5 vs. Level 1 [1900–440,000] vs. [2.2–290] 1.01 (0.90, 1.14) 0.8207
1994–2003 4 Exposure: Level 2 vs. Level 1 [9.8e-06–0.018] vs. [2e-13–9.8e-06] 1.02 (0.90, 1.15) 0.7864
Exposure: Level 3 vs. Level 1 [0.018–19] vs. [2e-13–9.8e-06] 1.24 (1.11, 1.39) 0.0001
Exposure: Level 4 vs. Level 1 [19–250] vs. [2e-13–9.8e-06] 1.31 (1.17, 1.47) <0.0001
Exposure: Level 5 vs. Level 1 [250–230,000] vs. [2e-13–9.8e-06] 1.41 (1.25, 1.58) <0.0001
1994–2003 8 Exposure: Level 2 vs. Level 1 [0.17–11] vs. [2.9e-05–0.17] 1.07 (0.95, 1.21) 0.2475
Exposure: Level 3 vs. Level 1 [11–270] vs. [2.9e-05–0.17] 1.26 (1.12, 1.40) 0.0001
Exposure: Level 4 vs. Level 1 [270–1300] vs. [2.9e-05–0.17] 1.42 (1.27, 1.60) <0.0001
Exposure: Level 5 vs. Level 1 [1300–370,000] vs. [2.9e-05–0.17] 1.41 (1.26, 1.58) <0.0001
1994–2003 16 Exposure: Level 2 vs. Level 1 [56–370] vs. [0.17–56] 1.22 (1.09, 1.38) 0.0009
Exposure: Level 3 vs. Level 1 [370–1600] vs. [0.17–56] 1.28 (1.14, 1.44) <0.0001
Exposure: Level 4 vs. Level 1 [1600–3900] vs. [0.17–56] 1.51 (1.35, 1.70) <0.0001
Exposure: Level 5 vs. Level 1 [3900–460,000] vs. [0.17–56] 1.37 (1.22, 1.54) <0.0001
1994–2003 24 Exposure: Level 2 vs. Level 1 [570–1800] vs. [3.9–570] 1.21 (1.08, 1.36) 0.0015
Exposure: Level 3 vs. Level 1 [1800–4100] vs. [3.9–570] 1.40 (1.26, 1.57) <0.0001
Exposure: Level 4 vs. Level 1 [4100–6200] vs. [3.9–570] 1.49 (1.33, 1.67) <0.0001
Exposure: Level 5 vs. Level 1 [6200–500,000] vs. [3.9–570] 1.25 (1.11, 1.41) 0.0002
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Table A3b
Negative binomial regression statistics for the 1994–2003 and the 1994–1998 exposure periods - FL.
Exposure period (Years) Scaling factor (km) Effect Level (in kg) Risk ratio 95% CI p-value
1994–1998 4 Exposure: Level 2 vs. Level 1 [8.2e-07–0.0038] vs. [3.3e-17–8.2e-07] 0.97 (0.83, 1.12) 0.6477
Exposure: Level 3 vs. Level 1 [0.0038–6.4] vs. [3.3e-17–8.2e-07] 1.22 (1.07, 1.40) 0.0028
Exposure: Level 4 vs. Level 1 [6.4–70] vs. [3.3e-17–8.2e-07] 1.26 (1.09, 1.45) 0.0018
Exposure: Level 5 vs. Level 1 [70–200,000] vs. [3.3e-17–8.2e-07] 1.03 (0.89, 1.20) 0.6756
1994–1998 8 Exposure: Level 2 vs. Level 1 [0.037–3.8] vs. [8.7e-07–0.037] 1.08 (0.94, 1.25) 0.2844
Exposure: Level 3 vs. Level 1 [3.8–98] vs. [8.7e-07–0.037] 1.26 (1.10, 1.44) 0.0009
Exposure: Level 4 vs. Level 1 [98–360] vs. [8.7e-07–0.037] 1.34 (1.17, 1.55) <0.0001
Exposure: Level 5 vs. Level 1 [360–320000] vs. [8.7e-07–0.037] 1.05 (0.90, 1.22) 0.5339
1994–1998 16 Exposure: Level 2 vs. Level 1 [23–160] vs. [0.12–23] 1.24 (1.08, 1.43) 0.0024
Exposure: Level 3 vs. Level 1 [160–630] vs. [0.12–23] 1.27 (1.11, 1.45) 0.0005
Exposure: Level 4 vs. Level 1 [630–1100] vs. [0.12–23] 1.26 (1.09, 1.46) 0.0019
Exposure: Level 5 vs. Level 1 [1100–410,000] vs. [0.12–23] 0.98 (0.84, 1.14) 0.8043
1994–1998 24 Exposure: Level 2 vs. Level 1 [290–1100] vs. [2.2–290] 1.21 (1.06, 1.38) 0.0046
Exposure: Level 3 vs. Level 1 [1100–1600] vs. [2.2–290] 1.26 (1.10, 1.44) 0.0007
Exposure: Level 4 vs. Level 1 [1600–1900] vs. [2.2–290] 1.16 (1.00, 1.34) 0.0448
Exposure: Level 5 vs. Level 1 [1900–440,000] vs. [2.2–290] 0.78 (0.67, 0.91) 0.0014
1994–2003 4 Exposure: Level 2 vs. Level 1 [9.8e-06–0.018] vs. [2e-13–9.8e-06] 0.96 (0.83, 1.11) 0.5606
Exposure: Level 3 vs. Level 1 [0.018–19] vs. [2e-13–9.8e-06] 1.19 (1.04, 1.35) 0.0113
Exposure: Level 4 vs. Level 1 [19–250] vs. [2e-13–9.8e-06] 1.20 (1.04, 1.39) 0.0116
Exposure: Level 5 vs. Level 1 [250–230,000] vs. [2e-13–9.8e-06] 1.03 (0.89, 1.20) 0.6614
1994–2003 8 Exposure: Level 2 vs. Level 1 [0.17–11] vs. [2.9e-05–0.17] 1.00 (0.86, 1.16) 0.9911
Exposure: Level 3 vs. Level 1 [11–270] vs. [2.9e-05–0.17] 1.19 (1.04, 1.36) 0.0105
Exposure: Level 4 vs. Level 1 [270–1300] vs. [2.9e-05–0.17] 1.27 (1.10, 1.46) 0.0009
Exposure: Level 5 vs. Level 1 [1300–370,000] vs. [2.9e-05–0.17] 1.06 (0.92, 1.23) 0.4385
1994–2003 16 Exposure: Level 2 vs. Level 1 [56–370] vs. [0.17–56] 1.23 (1.07, 1.42) 0.0043
Exposure: Level 3 vs. Level 1 [370–1600] vs. [0.17–56] 1.17 (1.02, 1.35) 0.0271
Exposure: Level 4 vs. Level 1 [1600–3900] vs. [0.17–56] 1.39 (1.20, 1.59) <0.0001
Exposure: Level 5 vs. Level 1 [3900–460,000] vs. [0.17–56] 1.05 (0.90, 1.22) 0.5115
1994–2003 24 Exposure: Level 2 vs. Level 1 [570–1800] vs. [3.9–570] 1.10 (0.96, 1.27) 0.1814
Exposure: Level 3 vs. Level 1 [1800–4100] vs. [3.9–570] 1.24 (1.09, 1.42) 0.0013
Exposure: Level 4 vs. Level 1 [4100–6200] vs. [3.9–570] 1.19 (1.03, 1.37) 0.0197
Exposure: Level 5 vs. Level 1 [6200–500,000] vs. [3.9–570] 0.93 (0.80, 1.08) 0.3386
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